{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:43:36Z","timestamp":1793720616659,"version":"4.6.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03485-z","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T08:06:51Z","timestamp":1739434011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease"],"prefix":"10.1186","volume":"27","author":[{"given":"Kaikai","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaikai","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"5","key":"3485_CR1","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3485_CR2","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/rheumatology\/keac627","volume":"62","author":"M Kogami","year":"2023","unstructured":"Kogami M, Abe Y, Ando T, et al. Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2023;62(7):2525\u201333.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"3485_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212709","volume":"77","author":"IE Lundberg","year":"2018","unstructured":"Lundberg IE, Tjarnlund A. Response to: \u201c2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?\u201d by Malaviya. Ann Rheum Dis. 2018;77(11):e78.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3485_CR4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","volume":"29","author":"A Vancsa","year":"2009","unstructured":"Vancsa A, Csipo I, Nemeth J, et al. Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009;29(9):989\u201394.","journal-title":"Rheumatol Int"},{"issue":"8","key":"3485_CR5","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","volume":"101","author":"HJ Won","year":"2007","unstructured":"Won HJ, Soon KD, Keun LC, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007;101(8):1761\u20139.","journal-title":"Respir Med"},{"key":"3485_CR6","doi-asserted-by":"crossref","unstructured":"Kuwana M, Gil-Vila A, Selva-O'Callaghan A. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2021;13:1759720X211032457.","DOI":"10.1177\/1759720X211032457"},{"key":"3485_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91\u20139.","journal-title":"Respir Med"},{"issue":"2","key":"3485_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003150","volume":"9","author":"X Chen","year":"2023","unstructured":"Chen X, Jiang W, Jin Q, et al. Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease. RMD Open. 2023;9(2):e003150.","journal-title":"RMD Open"},{"issue":"5","key":"3485_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1378\/chest.08-2740","volume":"136","author":"H Mukae","year":"2009","unstructured":"Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136(5):1341\u20137.","journal-title":"Chest"},{"issue":"12","key":"3485_CR10","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathiesand theirMajorSubgroups. Arthritis Rheumatol. 2017;69(12):2271\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"3485_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MCP.0b013e328363f48d","volume":"19","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD. Curr Opin Pulm Med. 2013;19(5):453\u20139.","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"3485_CR12","doi-asserted-by":"publisher","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","volume":"51","author":"AU Wells","year":"2018","unstructured":"Wells AU, Brown KK, Flaherty KR, et al. What\u2019s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1800692.","journal-title":"Eur Respir J"},{"key":"3485_CR13","doi-asserted-by":"crossref","unstructured":"Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018;27(150):180076.","DOI":"10.1183\/16000617.0076-2018"},{"issue":"3","key":"3485_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.4049\/jimmunol.1100857","volume":"187","author":"T Robinson","year":"2011","unstructured":"Robinson T, Kariuki SN, Franek BS, et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients. J Immunol. 2011;187(3):1298\u2013303.","journal-title":"J Immunol"},{"issue":"3","key":"3485_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.4049\/jimmunol.1102705","volume":"188","author":"SP Crampton","year":"2012","unstructured":"Crampton SP, Deane JA, Feigenbaum L, et al. Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity. J Immunol. 2012;188(3):1451\u20132145.","journal-title":"J Immunol"},{"issue":"16","key":"3485_CR16","doi-asserted-by":"publisher","first-page":"26552","DOI":"10.18632\/oncotarget.15716","volume":"8","author":"L Li","year":"2017","unstructured":"Li L, Wang Q, Yang F, et al. Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. Oncotarget. 2017;8(16):26552\u201364.","journal-title":"Oncotarget"},{"issue":"6","key":"3485_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","volume":"28","author":"M Fujimoto","year":"2016","unstructured":"Fujimoto M, Watanabe R, Ishitsuka Y, et al. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636\u201344.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"3485_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME Dewane","year":"2020","unstructured":"Dewane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3485_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.resinv.2016.09.006","volume":"55","author":"T Fujisawa","year":"2017","unstructured":"Fujisawa T, Hozumi H, Kono M, et al. Predictive factors for long-term outcome in polymyositis\/dermatomyositis-associated interstitial lung diseases. Respir Investig. 2017;55(2):130\u20137.","journal-title":"Respir Investig"},{"key":"3485_CR20","doi-asserted-by":"crossref","unstructured":"Kishaba T, Mcgill R, Nei Y, et al. Clinical characteristics of dermatomyosits\/polymyositis associated interstitial lung disease according to the autoantibody. J Med Invest. 2018;65(3.4):251\u20137.","DOI":"10.2152\/jmi.65.251"},{"issue":"8","key":"3485_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925\u201333.","journal-title":"Lupus"},{"key":"3485_CR22","doi-asserted-by":"publisher","first-page":"2024869","DOI":"10.1155\/2020\/2024869","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li Y, Li Y, Wu J, et al. Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis. J Immunol Res. 2020;2020:2024869.","journal-title":"J Immunol Res"},{"issue":"8","key":"3485_CR23","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013;65(8):1316\u201324.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3485_CR24","unstructured":"Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody:study of 121 cases. Neurology. 2020;95(1):e70\u20138."},{"key":"3485_CR25","doi-asserted-by":"crossref","unstructured":"Xu L, You H, Wang L, et al. Identification of three different phenotypes in anti-MDA5 antibody-positive dermatomyositis patients:implications for rapidly progressive interstitial lung disease prediction. Arthritis Rheumatol. 2023;75(4):609\u201319.","DOI":"10.1002\/art.42308"},{"issue":"2","key":"3485_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjd.14882","volume":"176","author":"T Matsushita","year":"2017","unstructured":"Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176(2):395\u2013402.","journal-title":"Br J Dermatol"},{"issue":"6","key":"3485_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.resinv.2018.07.007","volume":"56","author":"S Sakamoto","year":"2018","unstructured":"Sakamoto S, Okamoto M, Kaieda S, et al. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Respir Investig. 2018;56(6):464\u201372.","journal-title":"Respir Investig"},{"issue":"1","key":"3485_CR28","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1111\/jdv.13670","volume":"31","author":"C Murase","year":"2017","unstructured":"Murase C, Muro Y, Akiyama M. Rapid increase of serum anti-MDA-5 antibodies and exacerbation of clinically amyopathic dermatomyositis\/interstitial lung disease. J Eur Acad Dermatol Venereol. 2017;31(1):e43\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3485_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","volume":"29","author":"A Nishioka","year":"2019","unstructured":"Nishioka A, Tsunoda S, Abe T, et al. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod Rheumatol. 2019;29(5):814\u201320.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"3485_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","volume":"78","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Pinal-Fernandez I, Kishi T, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019;78(7):988\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"3485_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015578","volume":"98","author":"J Temmoku","year":"2019","unstructured":"Temmoku J, Sato S, Fujita Y, et al. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis\/dermatomyositis. Medicine (Baltimore). 2019;98(20):e15578.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"3485_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1684\/ejd.2019.3634","volume":"29","author":"SI Motegi","year":"2019","unstructured":"Motegi SI, Sekiguchi A, Toki S, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol. 2019;29(5):511\u20137.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"3485_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5606\/ArchRheumatol.2018.6419","volume":"33","author":"Q Jin","year":"2018","unstructured":"Jin Q, Zheng J, Xu X, et al. Value of Serum Carbohydrate Antigen 19\u20139 and Carcinoembryonic Antigen in Evaluating Severity and Prognosis of Connective Tissue Disease-Associated Interstitial Lung Disease. Arch Rheumatol. 2018;33(2):190\u20137.","journal-title":"Arch Rheumatol"},{"issue":"8","key":"3485_CR34","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/j.1440-1843.2012.02231.x","volume":"17","author":"A Fahim","year":"2012","unstructured":"Fahim A, Crooks MG, Wilmot R, et al. Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis. Respirology. 2012;17(8):1247\u201352.","journal-title":"Respirology"},{"issue":"3","key":"3485_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2169\/internalmedicine1962.24.236","volume":"24","author":"H Takahashi","year":"1985","unstructured":"Takahashi H, Nukiwa T, Matsuoka R, et al. Carcinoembryonic antigen in bronchoalveolar lavage fluid in patients with idiopathic pulmonary fibrosis. Jpn J Med. 1985;24(3):236\u201343.","journal-title":"Jpn J Med"},{"issue":"1","key":"3485_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13104-018-3146-7","volume":"11","author":"K Yamada","year":"2018","unstructured":"Yamada K, Asai K, Okamoto A, et al. Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report. BMC Res Notes. 2018;11(1):34.","journal-title":"BMC Res Notes"},{"issue":"5","key":"3485_CR37","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","volume":"107","author":"K Tanizawa","year":"2013","unstructured":"Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013;107(5):745\u201352.","journal-title":"Respir Med"},{"issue":"4","key":"3485_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.41566","volume":"73","author":"T Gono","year":"2021","unstructured":"Gono T, Masui K, Nishina N, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 2021;73(4):677\u201386.","journal-title":"Arthritis Rheumatol"},{"issue":"18","key":"3485_CR39","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2169\/internalmedicine.47.0967","volume":"47","author":"W Ishii","year":"2008","unstructured":"Ishii W, Matsuda M, Shimojima Y, et al. Flow cytometric analysis of lymphocyte subpopulations and TH1\/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med. 2008;47(18):1593\u20139.","journal-title":"Intern Med"},{"key":"3485_CR40","doi-asserted-by":"crossref","unstructured":"Yousaf MN, Powell MD. The effects of heart and skeletal muscle inflammation and cardiomyopathy syndrome on creatine kinase and lactate dehydrogenase levels in Atlantic salmon (Salmo salar L.). Scientific World Journal. 2012;2012:741302.","DOI":"10.1100\/2012\/741302"},{"issue":"4","key":"3485_CR41","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","volume":"158","author":"X Lian","year":"2020","unstructured":"Lian X, Zou J, Guo Q, et al. Mortality risk prediction in amyopathic dermatomyositis associated with Interstitial lung disease: The FLAIR Model. Chest. 2020;158(4):1535\u201345.","journal-title":"Chest"},{"issue":"10","key":"3485_CR42","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1093\/rheumatology\/keaa034","volume":"59","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, Ye L, Liu M, et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology (Oxford). 2020;59(10):2829\u201337.","journal-title":"Rheumatology (Oxford)"},{"key":"3485_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6819","volume":"352","author":"SC Mathai","year":"2016","unstructured":"Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.","journal-title":"BMJ"},{"issue":"1","key":"3485_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","volume":"29","author":"H Kohsaka","year":"2019","unstructured":"Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol. 2019;29(1):1\u201319.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"3485_CR45","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1007\/s12325-019-00992-9","volume":"36","author":"TM Maher","year":"2019","unstructured":"Maher TM, Wuyts W. Management of fibrosing interstitial lung diseases. Adv Ther. 2019;36(7):1518\u201331.","journal-title":"Adv Ther"},{"key":"3485_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743977","volume":"8","author":"CR Copeland","year":"2021","unstructured":"Copeland CR, Lancaster LH. Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Front Med (Lausanne). 2021;8:743977.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3485_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5152\/eurjrheum.2015.0076","volume":"2","author":"K Hamada-Ode","year":"2015","unstructured":"Hamada-Ode K, Taniguchi Y, Kimata T, et al. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. Eur J Rheumatol. 2015;2(2):83\u20135.","journal-title":"Eur J Rheumatol"},{"issue":"12","key":"3485_CR48","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53(12):2196\u2013203.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3485_CR49","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","volume":"147","author":"W Damsky","year":"2021","unstructured":"Damsky W, Peterson D, Ramseier J, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021;147(3):814\u201326.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3485_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","volume":"81","author":"X Kong","year":"2022","unstructured":"Kong X, Sun Y, Dai X, et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis. 2022;81(1):117\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3485_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated Interstitial Lung Disease. N Engl J Med. 2019;381(3):291\u20133.","journal-title":"N Engl J Med"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03485-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03485-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03485-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:34:35Z","timestamp":1739820875000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03485-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3485"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03485-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The collection and review of the clinical data for this study and research implementation were approved by the Ethics Committee of the Second Affiliated Hospital, Xi\u2019an Jiaotong University on 27 January 2023. All patients (or their guardians) included in the study were issued an informed consent form, which they read and understood before signing to indicate their full understanding of the research. The study was conducted in accordance with the 1964 Declaration of Helsinki and its subsequent amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}